Press release
Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of Targeted Therapies | DelveInsight
Anti-CD20 Antibody Pipeline
DelveInsight's "Anti-CD20 Antibody Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Anti-CD20 Antibody market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging anti-CD20 antibody drugs, the anti-CD20 antibody pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Anti-CD20 Antibody Pipeline Report
• DelveInsight's anti-CD20 antibody Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline drugs for anti-CD20 antibody treatment.
• The leading anti-CD20 antibody companies include TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others are evaluating their lead assets to improve the Anti-CD20 Antibody treatment landscape.
• Key anti-CD20 antibody pipeline therapies in various stages of development include Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.
• In March 2025, Roche announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for GAZYVA®/GAZYVARO® (obinutuzumab) for treating lupus nephritis. The acceptance is based on positive Phase III REGENCY study results, which showed improved complete renal response when Gazyva was added to standard therapy.
• In February 2025, Regeneron announced that the FDA accepted the resubmitted Biologics License Application (BLA) for odronextamab to treat relapsed/refractory follicular lymphoma (FL) after two or more prior therapies. The FDA's target decision date is July 30, 2025.
• In March 2024, BeiGene announced that the FDA granted accelerated approval to BRUKINSA® (zanubrutinib), in combination with obinutuzumab, for treating adults with relapsed or refractory follicular lymphoma (FL) after two or more prior therapies.
• In August 2024, Indapta Therapeutics announced that the FDA cleared the IND for its Phase 1 trial of IDP-023, a g-natural killer (g-NK) cell therapy, for the treatment of progressive multiple sclerosis (MS).
Request a sample and discover the recent breakthroughs happening in the anti-CD20 antibody pipeline landscape @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Overview
CD20 is a non-glycosylated phosphoprotein, weighing 33-37 kDa, found on the surface of mature, undifferentiated B cells. Its expression begins at the pre-B-cell stage and continues until the cell differentiates into a plasma cell. Due to its consistent and high-level expression on malignant B cells, CD20 has become a key therapeutic target. Structurally, CD20 includes four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops (one large and one small), with both the N- and C-termini located within the cytoplasm.
The widespread presence of CD20 on transformed B cells underlies the development of anti-CD20 monoclonal antibodies (mAbs), which are used to deplete B cells. Initially designed to treat B cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), anti-CD20 therapies are now widely used for conditions characterized by high CD20 expression. These antibodies rank among the most effective therapies in both oncology and immune-related disorders.
Find out more about anti-CD20 antibody medication @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Treatment Analysis: Drug Profile
Ublituximab: TG Therapeutics
Ublituximab (TG-1101) is an investigational, glycoengineered anti-CD20 monoclonal antibody that targets a unique epitope on CD20-positive B cells. Upon binding, it initiates immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell destruction. TG Therapeutics has completed a rolling Biologics License Application (BLA) submission to the FDA for ublituximab as a treatment for chronic lymphocytic leukemia (CLL). The FDA has granted Fast Track designation to the ublituximab-umbralisib (U2) combination and Orphan Drug status for the same indication.
Glofitamab: Roche
Glofitamab (RO7082859, RG6026) is an investigational bispecific antibody that targets both CD20 on malignant B cells and CD3 on T cells, redirecting T cells to attack cancerous B cells. It is currently being evaluated in a Phase III trial comparing glofitamab + gemcitabine + oxaliplatin to rituximab + gemcitabine + oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Key Anti-CD20 Antibody Therapies and Companies
• Ublituximab: TG therapeutics
• Glofitamab: Roche
Learn more about the novel and emerging anti-CD20 antibody pipeline therapies @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Anti-CD20 Antibody Pipeline Report
• Coverage: Global
• Key Anti-CD20 Antibody Companies: TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others.
• Key Anti-CD20 Antibody Pipeline Therapies: Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.
Dive deep into rich insights for drugs used for anti-CD20 antibody treatment; visit @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Anti-CD20 Antibody Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Anti-CD20 Antibody Pipeline Therapeutics
6. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
7. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
8. Anti-CD20 Antibody Pipeline: Mid-Stage Products (Phase II)
9. Anti-CD20 Antibody Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of Targeted Therapies | DelveInsight here
News-ID: 3965890 • Views: …
More Releases from DelveInsight
Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunothe …
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and progression through targeted and immune-based therapies, and (2) improve patient survival, quality of life, and functional outcomes. Current programs include EGFR, ALK, KRAS, and MET inhibitors, immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), and emerging bispecific antibodies and combination regimens designed to overcome resistance and enhance efficacy.
Late-stage…
Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve sheath tumors (MPNST) while improving quality of life. Current programs include RAS-MAPK pathway inhibitors, next-generation MEK inhibitors, mTOR modulators, immuno-oncology agents for MPNST, and early gene-directed therapies.
Late-stage trials primarily test oral RAS pathway inhibitors for pediatric plexiform neurofibromas, with attention to safety, functional improvement, and…
Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through next-generation multivalent and protein-based vaccines, and (2) improve long-term immunity and reduce disease incidence in adolescents, young adults, and high-risk populations. Ongoing programs include conjugate vaccines, adjuvanted formulations, and combination vaccines targeting meningococcal and other pediatric pathogens to optimize immunization schedules.
Late-stage and pivotal trials focus…
Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor control, and (2) enhance patient quality of life and daily functioning. Ongoing programs include small-molecule pharmacologics targeting GABAergic and calcium channel pathways, focused ultrasound neuromodulation, deep brain stimulation (DBS) refinements, and emerging gene therapy candidates aimed at long-term tremor suppression.
Late-stage and registration-enabling trials assess efficacy,…
More Releases for CD20
Anti-CD20 Monoclonal Antibodies (MAbs) Market Is Booming So Rapidly | Pfizer, Te …
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market Size is estimated at $12.8 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.2% to reach $30.7 Billion by 2034.
The latest study released on the Global Anti-CD20 Monoclonal Antibodies (MAbs) Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Anti-CD20 Monoclonal Antibodies (MAbs) market study covers significant research data and proofs to…
CD20 Antibody Market Forecast 2025-2034: Analysing Major Trends, Opportunities, …
Which drivers are expected to have the greatest impact on the over the cd20 antibody market's growth?
The increasing incidence of B-cell malignancies is also expected to propel the growth of the CD-20 antibody market. These malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, are on the rise due to factors like aging and genetic predisposition. CD20 antibodies, such as rituximab, target malignant B-cells to improve therapeutic outcomes. According to…
Anti-CD20 Antibody Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight 2024" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Anti-CD20 Antibody Pipeline, FDA Approvals, Clinical Trials Developments and Com …
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
CD20 Monoclonal Antibodies Market is growing at a healthy CAGR of 8.4% by 2028
The CD20 monoclonal antibodies market is estimated to gain market growth in the upcoming forecasted years. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.4% in the above-mentioned research forecast period. The increasing R&D in generating potent CD20 monoclonal antibodies will drive the market.
The demand of CD20 monoclonal antibodies market has increased significantly because of advancements in technology, increasing demand of immunotherapy and fewer…
CD20 Monoclonal Antibodies Market is growing at a healthy CAGR of 8.4%
The CD20 monoclonal antibodies market is estimated to gain market growth in the upcoming forecasted years. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.4% in the above-mentioned research forecast period. The increasing R&D in generating potent CD20 monoclonal antibodies will drive the market.
The demand of CD20 monoclonal antibodies market has increased significantly because of advancements in technology, increasing demand of immunotherapy and fewer…
